Jihad Irani
Family Medicine · Burgettstown, PANPI 1568591907
Payments from drug & device makers
Across 227 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$884
- AbbVie$709
- Lilly USA, LLC$434
- GSK$372
- AstraZeneca$262
- Merck$251
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,085100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $884 |
| AbbVie | 39 | $709 |
| Lilly USA, LLC | 25 | $434 |
| GSK | 21 | $372 |
| AstraZeneca | 11 | $262 |
| Merck | 15 | $251 |
| Pfizer | 9 | $162 |
| Abbott | 6 | $113 |
| Verona Pharma, Inc. | 5 | $100 |
| Boehringer Ingelheim | 5 | $75 |
| Dexcom, Inc. | 4 | $71 |
| Medtronic | 2 | $68 |
| Exact Sciences | 4 | $66 |
| Organon | 4 | $61 |
| Sanofi Pasteur Inc. | 3 | $56 |
| Amgen(2 entities) | 3 | $53 |
| Seqirus USA Inc | 2 | $53 |
| Bayer | 2 | $49 |
| Johnson & Johnson | 2 | $44 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Edwards Lifesciences | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Roche Diagnostics Corporation | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$4,085 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $107,315 |
| JardianceEmpagliflozin | 49 | $42,927 |
| EliquisApixaban | 47 | $33,310 |
| FarxigaDapagliflozin Propanediol | 54 | $32,564 |
| MounjaroTirzepatide | 27 | $28,201 |
| TrulicityDulaglutide | 23 | $24,405 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $18,793 |
| RybelsusSemaglutide | 18 | $18,320 |
| Spiriva RespimatTiotropium Bromide | 16 | $12,150 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $11,627 |
| LinzessLinaclotide | 20 | $11,002 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $9,908 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $7,882 |
| MyrbetriqMirabegron | 15 | $6,529 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $5,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $884 | $125,636122 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $75 | $64,98578 claims |
| Lilly USA, LLCMounjaro, Trulicity | $434 | $52,60650 claims |
| PfizerEliquis | $162 | $33,31047 claims |
| AstraZenecaFarxiga | $262 | $32,56454 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $372 | $30,41957 claims |
| AbbVieLinzess, Synthroid | $709 | $12,58350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Burgettstown
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.